10.07.2012 - The European Commission has authorised the import of Monsanto’s soya which bears additional genes for a herbicide tolerance and an insecticide.
Just a few days after the European Food Safety Authority (EFSA) had approved the cultivation of genetically modified (GM) soya on European soils, the European Commission agreed on another soya matter. On 27 June, without public communication, the Commission authorised Monsanto Company’s genetically engineered soya Intacta RR2 Pro for import to the European Union. These soya plants harbour a combination of gene constructs that convey both tolerance for herbicides and resistance to insects. More specifically, Intacta is a combination of soys MON87701 and MON89788 which produce an insecticidal Bt protein and is tolerant to the herbicide glyphosate, respectively. It is the first time in the EU that gm-soya with stacked gene constructs has been allowed for usage in food and feed.
On 6 July the Brazilian Association of Seeds and Seedlings (ABRASEM) issued a statement „celebrating the opening of new doors to varieties of high technology seeds.“ Brazil is the main beneficiary of the authorisation as Monsanto’s soya is grown and harvested there. Europe is the second main destination of Brazilian soya exports, with China leading the chart. However, Intacta is not yet approved by China so that the European decision could very well be interpreted as trend-setting.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.